Current Report Filing (8-k)
September 12 2016 - 7:31AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): September 6, 2016
RELMADA
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
333-184881
|
|
45-5401931
|
(State
or other jurisdiction of
|
|
(Commission
File Number)
|
|
(IRS
Employer
|
incorporation)
|
|
|
|
Identification
No.)
|
275
Madison Avenue Avenue, STE #702
New
York, NY
|
|
10016
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code
(646) 677-3853
N/A
|
(Former
name or former address, if changed since last report)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
7.01. Regulation FD Disclosure.
Relmada
Alleges Additional Claims Against Laidlaw & Co. (UK) Ltd. (“Laidlaw”), Matthew D. Eitner and James P. Ahern
On
September 6, 2016, Relmada Therapeutics, Inc. (“Relmada”) moved the United States District Court, District of Nevada
for leave to amend its complaint against Laidlaw, Mathew D. Eitner and James P. Ahern (the “Defendants”) for a second
time. The proposed pleading (the “Proposed Second Amended Complaint”) alleges additional claims against the Defendants,
including defamation/business disparagement, defamation per se, tortious interference with prospective economic advantage, violations
of sections 1962(c) and 1962(d) of the Racketeer Influenced and Corrupt Organizations Act, and violation of Section 10(b) of the
Securities Exchange Act of 1934 and Rule 10b-5 thereunder. Relmada believes that it has incurred substantial damages from Defendants’
actions, which are addressed in the Proposed Second Amended Complaint.
A
copy of the Proposed Second Amended Complaintis attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
into this Item 7.01 by reference. In accordance with General Instruction B.2 of Form 8-K, the information set forth herein
is deemed to be "furnished" and shall not be deemed to be "filed" for purposes of the Securities Exchange
Act of 1934, as amended. The information set forth in Item 7.01 of this Current Report on Form 8-K shall not be deemed an admission
as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely to satisfy
the requirements of Regulation FD.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit
No.
|
|
|
Description
|
|
99.1
|
|
|
Proposed Second Amended Complaint, filed September 6, 2016.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Dated:
September 12, 2016
|
RELMADA
THERAPEUTICS, INC.
|
|
|
|
|
|
By:
|
/s/
Sergio Traversa
|
|
|
Name:
|
Sergio
Traversa
|
|
|
Title:
|
Chief
Executive Officer
|
3